Anesiva receives notification letter from NASDAQ Stock Market

NewsGuard 100/100 Score

Anesiva, Inc. (Nasdaq: ANSV) announced today that on December 2, 2009, Anesiva received a letter from The NASDAQ Stock Market ("Nasdaq") stating that Anesiva was required to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $5,000,000 during the last 30 consecutive business days and that therefore

Anesiva was not in compliance with Listing Rule 5450(b)(1)(C). The notification letter has no effect at this time on the listing of Anesiva's common stock on The NASDAQ Global Market and Anesiva's common stock will continue to trade on The NASDAQ Global Market under the symbol ANSV.

The notification letter states that Anesiva will be afforded a grace period of 90 calendar days, or until March 2, 2010, to regain compliance with the minimum closing bid price requirement. If at anytime during this grace period Anesiva's MVPHS closes at $5,000,000 or more for a minimum of ten consecutive business days, Nasdaq will provide a written confirmation of compliance and the matter will be closed.

If Anesiva does not regain compliance by March 2, 2010, Nasdaq will provide written notification to Anesiva that its common stock may be delisted. Alternatively, Anesiva may want to consider applying for a transfer to The Nasdaq Capital Market, provided it satisfies the requirements for continued listing on that market.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.